Scil Technology GmbH, a German biopharmaceutical development company, and Medtronic’s biologics company, based in Memphis, TN, are partnering in an effort to develop new treatment options for periodontal and bone regeneration. Scil Technology will bring rhGDF-5, a human growth factor, and R&D to the table, while Medtronic will oversee clinical trials, regulatory approvals, and commercialization of the final product. With about a million people who need dental restoration or periodontal therapy, the results of the partnership will help many patients who have unmet needs in this area. Dentists will have more options on how to improve overall oral health.
SOURCE: Medical News Today